Why the study?
Does sacubitril/valsartan added to amlodipine improve blood pressure control in Asian hypertensive patients uncontrolled on amlodipine alone?
Does sacubitril/valsartan added to amlodipine improve blood pressure control in Asian hypertensive patients uncontrolled on amlodipine alone?
Answers are grounded in this paper and cite their sources.
While sacubitril/valsartan effectively lowers blood pressure in patients uncontrolled on amlodipine, future studies should use active comparators to define its exact clinical utility in hypertension management.
In the last 20 years, no new drug with an innovative mechanism of action has been developed and reached the market for the treatment of hypertension. Innovation in antihypertensive therapy has been characterized essentially by the development of single pill combinations associating angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) with calcium channel blockers or diuretics or both [1]. In the 1990s, the concept of vasopeptidase inhibition was elaborated [2]. It involved the simultaneous inhibition of two important enzymatic cascades implicated in blood pressure (BP) regulation, that is the renin–angiotensin system by inhibiting ACE and the natriuretic peptide system by inhibiting the neutral endopeptidase EC 24.11 (neprilysin) leading to an increase in the vasodilatatory, natriuretic and antiproliferative properties of these peptides. This very interesting concept was put in concrete form with omapatrilat, a compound which had the capacity to inhibit both enzymes and which was found to have a superior antihypertensive efficacy compared with other classes to provide target organ protection in humans and to reduce morbidity and mortality from cardiovascular events in animal models. On the contrary, this drug was withdrawn before it actually reached the market because of an increased incidence of life-threatening angioedema due to the double enzymatic inhibition leading to significant increases in vasoactive peptides among which bradykinin that contributes to the pathophysiology of angioedema [3,4]. Moreover, per se, neprilysin inhibition was not found to have sufficient BP-lowering effects to be developed as a new antihypertensive agent [5]. Yet, the principle of combining a blocker of the renin–angiotensin system with an inhibitor of the degradation of natriuretic peptides remained appealing. It was revived with the ability to block the renin–angiotensin system more selectively at the angiotensin II AT1 receptor site thereby preventing the accumulation of peptides with undesirable clinical effects [6]. This is the basis on which the association of sacubitril, a neprilysin inhibitor and valsartan, an ARB, was developed to create LCZ696. In contrast to omapatrilat that was a single molecule, this NEP/ARB is a clever chemical single pill combination of the two compounds. Today, it is the first NEP/ARB inhibitor on the market. So far, it has been developed clinically primarily for heart failure where it is now recommended for the treatment of symptomatic patients with heart failure and a reduced ejection fraction based on the results of the PARADIGM-HF trial [7–9]. In hypertension, two major studies have investigated the antihypertensive efficacy and the safety of sacubitril/valsartan in humans [10,11]. The first study compared the efficacy of three doses of LCZ696 [100, 200 and 400 mg once daily (od)] to three doses of valsartan (80, 160 and 320 mg od) to a placebo and 200 mg of the neprilysin inhibitor alone [10]. It was conducted in patients with mild-to-moderate hypertension either previously untreated or after a washout period. The results showed a significantly greater decrease in both office and ambulatory BP with the sacubitril/valsartan combination when 200 and 400 mg of the association were compared with 160 and 320 mg of valsartan, respectively. There were no safety issues in this 8-week study. The second study was performed in Asia and compared three doses of the association (100, 200 and 400 mg od) to placebo in patients with mild-to-moderate essential hypertension [11]. The study design was very similar to the previous study except that changes in ambulatory BP were the primary end-point. Once again, sacubitril/valsartan was found to have significantly greater BP-lowering effect than the placebo at all three doses and whatever the method of BP assessment. The safety was excellent with no case of angioedema. In this issue of the Journal, a new study is published which evaluates the antihypertensive efficacy of sacubitril/valsartan in an Asian hypertensive population uncontrolled with amlodipine [12]. After a 4-week single-blind run-in phase in which all patients received 5-mg amlodipine, patients not adequately controlled with a mean office SBP more than 145 and less than 180 mmHg were randomized to sacubitril/valsartan 200 mg + amlodipine 5 mg or to amlodipine 5 mg + placebo for 8 weeks. The main endpoint was the change in 24-h ambulatory BP. Based on ambulatory BP, the NEP/ARB association induced a significantly greater decrease in BP when compared with the placebo group maintained on amlodipine 5 mg. Based on office BP, a similar finding was observed though a significant decrease in office BP was also found in the amlodipine + placebo group. A greater percentage of patients had a well controlled office BP at week when receiving 200-mg sacubitril/valsartan for 8 weeks. The safety of the association was once again considered as excellent. Are these results of any surprise? Certainly not! Patients were selected for randomization based on their unsatisfactory response to 4 weeks of amlodipine 5 mg. Thus, the only surprise was that office BP continued to decrease during the next eight following weeks when a placebo was added. This once more reflects the major placebo effect and the regression to the mean commonly seen in pharmacological studies when the primary endpoint is office BP. Indeed, no placebo effect was observed in this group when BP was measured using ambulatory BP monitoring. This would confirm that all studies investigating the efficacy of antihypertensive drugs should be monitored using out-of-office BP either as a primary endpoint or at least in a subgroup of the treated population. This was actually done in the sacubitril/valsartan development program in hypertension. The fact that a combination of two vasoactive substances combined in a single drug was more effective than placebo to lower BP in amlodipine-treated patients is almost trivial. Indeed, sacubitril/valsartan has been shown to be superior to placebo already in the two studies discussed above including in an Asiatic population [10,11]. So what is new? In fact, the design of this study really questions what would have been the adequate control group to assess not only the efficacy of sacubitril/valsartan but also its clinical usefulness in terms of hypertension management. For example, patients could have been randomized to amlodipine 10 mg (5 + 5) or sacubitril/valsartan + amlodipine 5 mg. Indeed, in clinical practice and according to guidelines, a patient uncontrolled with amlodipine 5 mg would either be switched to a combination therapy or to a higher dose of amlodipine. In a retrospective analysis of data pooled from two Phase III/IV open-label Asian studies, uptitrating the dose of amlodipine from 5 to 10 mg daily was associated with significant decreases in both SBP and DBP that were almost comparable with those reported with the addition of sacubitril/valsartan [13]. Alternatively, if one considers sacubitril/valsartan as a single pill combination, the authors could also have randomized their patients to valsartan 160 mg/amlodipine 5 mg on one side and to sacubitril/valsartan 200 mg + amlodipine 5 mg on the other. Such a design would have informed us on the real added value of neprilysin inhibition on top of blockade of the renin–angiotensin system and a calcium channel blocker. These study designs might be less favorable for the new combination. However, it would offer physicians a clearer profile for the place of any new drug in hypertension management corresponding to clinical practice rather than to authorities’ recommendations or industrial objectives. Today, we should stop designing clinical studies in which single pill combinations, associating two or three active compounds known to be superior to placebo, are compared with a single therapy as it is obvious that two or three drugs are more effective than one in hypertension. The safety profile of sacubitril/valsartan was comparable with that of amlodipine in this study with no angioedema reported during the 8 weeks of treatment. This confirms the observations made in the two previous studies but at this point, one must acknowledge that although angioedema is more likely to occur early after initiation of therapy, it may occur at any time [14]. Thus, clinical studies of longer duration are needed. Looking carefully at the incidence of adverse events in this study, some figures are puzzling. For example, an 11% incidence of orthostatic hypotension is reported in the amlodipine group. This is very unusual and not a classically reported adverse effect of amlodipine. In addition, hypokalemia was found in 1.5% of participants randomized to sacubitril/valsartan, but 15% of them had an episode of serum potassium less than 3.5 mmol/l which is actually the definition of hypokalemia. This may be read as a potential contradiction. Yet, this is rather surprising because neither valsartan nor sacubitril is supposed to lower serum potassium. In fact, earlier studies have demonstrated that natriuretic peptides inhibit aldosterone and have weak, if any, effect on urinary potassium excretion [15,16]. Therefore, there must be some other cause for the low serum potassium levels measured in this study. Significantly, neprilysin inhibition could be considered as a physiological diuretic that has the advantage of having no effect on serum potassium or serum uric acid levels. Therefore, neprilysin inhibition can potentiate the BP-lowering effects of blockade of the renin–angiotensin system like a diuretic but without its biochemical adverse effects. Taken together, the data available so far on the safety and antihypertensive efficacy of NEP/ARB inhibition induced by sacubitril/valsartan suggest that there might be a place for this new drug association in the management of hypertension. However, studies should be designed to clarify the place of this association in the treatment of hypertension. As suggested recently, more studies should be conducted in specific populations of hypertensive patients such as elderly patients or patients with diabetes, or chronic kidney disease [17]. The impact of the new single pill combination on target organ damage should also be investigated but with adequate control groups. Some of these studies are ongoing, and we look forward to see their results to fully appreciate the added clinical benefits of inhibiting simultaneously neprilysin and the renin–angiotensin system. ACKNOWLEDGEMENTS I thank Dr G. Wuerzner for the relecture. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Michel Burnier (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: